New Probiotics Product Contract with Access Business Group
HEM파마
376270
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=847
Risk-adjusted indicator based on 847 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Contract Amount: 4,634,589,030 KRW (USD 3,017,900)
- • Percentage of Recent Revenue: 35.71%
- • Recent Annual Revenue (2025): 12,979,352,490 KRW
- • Contract Start Date: 2026-06-23
- • Contract End Date: 2026-10-09
AI Analysis Summary
HEM Pharma Inc. secured a contract for new probiotics products with Access Business Group, valued at 4,634,589,030 KRW (USD 3,017,900). This represents a significant 35.71% of the company's 2025 annual revenue of 12,979,352,490 KRW. The contract period is from June 23, 2026, to October 9, 2026, with payment due within 60 days of invoice receipt. This substantial contract is expected to have a positive impact on future revenue and profitability, especially given the recurring nature of past contracts with the same counterparty.
How This Event Is Evaluated
Strategic Contract Evaluation
Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Contract size relative to company revenue
- Expected revenue impact
- Counterparty quality
- Contract duration and execution period
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.